{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:09:22Z","timestamp":1794546562600,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s13555-024-01188-y","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T12:02:45Z","timestamp":1717070565000},"page":"1615-1631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity"],"prefix":"10.1007","volume":"14","author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarannum","family":"Jaleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saakshi","family":"Khattri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2203-010X","authenticated-orcid":false,"given":"Cameron C.","family":"Helt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Malatestinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus E.","family":"Ngantcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"issue":"4","key":"1188_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10067-014-2652-9","volume":"34","author":"R Peluso","year":"2015","unstructured":"Peluso R, Iervolino S, Vitiello M, Bruner V, Lupoli G, Di Minno MN. Extra-articular manifestations in psoriatic arthritis patients. Clin Rheumatol. 2015;34(4):745\u201353.","journal-title":"Clin Rheumatol"},{"issue":"Suppl 2","key":"1188_CR2","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1188_CR3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1080\/09546634.2021.1942423","volume":"33","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb AB, Merola JF. A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis. J Dermatolog Treat. 2022;33(4):1907\u201315.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1188_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jaad.2021.09.019","volume":"86","author":"JF Merola","year":"2022","unstructured":"Merola JF, Tian H, Patil D, et al. Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health records database in the United States. J Am Acad Dermatol. 2022;86(4):748\u201357.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1188_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2340\/00015555-1833","volume":"94","author":"K de Vlam","year":"2014","unstructured":"de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014;94(6):627\u201334.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1188_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1590\/S0482-50042012000100010","volume":"52","author":"C Goldenstein-Schainberg","year":"2012","unstructured":"Goldenstein-Schainberg C, Favarato MH, Ranza R. Current and relevant concepts in psoriatic arthritis. Rev Bras Reumatol. 2012;52(1):98\u2013106.","journal-title":"Rev Bras Reumatol"},{"key":"1188_CR7","first-page":"2854","volume":"71","author":"K Tas\u00e7\u0131lar","year":"2019","unstructured":"Tas\u00e7\u0131lar K, Ayd\u0131n SZ, Akar S, et al. Delay between the onset of psoriasis and arthritis in PsA patients from the PsART international cohort. Arthritis Rheumatol. 2019;71:2854.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1188_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000867","volume":"5","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Etzel CJ, Huster WJ, et al. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. RMD Open. 2019;5(1):e000867.","journal-title":"RMD Open"},{"issue":"3","key":"1188_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40744-020-00221-8","volume":"7","author":"W Tillett","year":"2020","unstructured":"Tillett W, Merola JF, Thaci D, et al. Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey. Rheumatol Ther. 2020;7(3):617\u201337.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"1188_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40744-018-0120-8","volume":"5","author":"K de Vlam","year":"2018","unstructured":"de Vlam K, Merola JF, Birt JA, et al. Skin involvement in psoriatic arthritis worsens overall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational, cross-sectional study. Rheumatol Ther. 2018;5(2):423\u201336.","journal-title":"Rheumatol Ther"},{"issue":"5","key":"1188_CR11","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/bjd.13647","volume":"172","author":"IM Skoie","year":"2015","unstructured":"Skoie IM, Ternowitz T, Jonsson G, Norheim K, Omdal R. Fatigue in psoriasis: a phenomenon to be explored. Br J Dermatol. 2015;172(5):1196\u2013203.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1188_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1136\/ard.2008.098202","volume":"68","author":"JA Husted","year":"2009","unstructured":"Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD. Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis. 2009;68(10):1553\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1188_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10067-015-3035-6","volume":"35","author":"CL Overman","year":"2016","unstructured":"Overman CL, Kool MB, Da Silva JA, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol. 2016;35(2):409\u201315.","journal-title":"Clin Rheumatol"},{"issue":"9507","key":"1188_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0140-6736(06)68073-2","volume":"367","author":"JB Prins","year":"2006","unstructured":"Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome. Lancet. 2006;367(9507):346\u201355.","journal-title":"Lancet"},{"issue":"4\u20135","key":"1188_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"E Suzuki","year":"2014","unstructured":"Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13(4\u20135):496\u2013502.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1188_CR16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10067-015-2961-7","volume":"34","author":"SK Raychaudhuri","year":"2015","unstructured":"Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol. 2015;34(6):1019\u201323.","journal-title":"Clin Rheumatol"},{"issue":"9993","key":"1188_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase\u00a03 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"6","key":"1188_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047\u201358.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1188_CR19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","volume":"177","author":"K Reich","year":"2017","unstructured":"Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase\u00a0III study. Br J Dermatol. 2017;177(4):1014\u201323.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1188_CR20","doi-asserted-by":"publisher","first-page":"2160196","DOI":"10.1080\/09546634.2022.2160196","volume":"34","author":"A Reich","year":"2023","unstructured":"Reich A, Reed C, Schuster C, Robert C, Treuer T, Lubrano E. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016\u20132021. J Dermatol Treat. 2023;34(1):2160196.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1188_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s12325-022-02379-9","volume":"40","author":"C Lynde","year":"2023","unstructured":"Lynde C, Riedl E, Maul JT, et al. Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week\u00a012 from the PSoHO study in a real-world setting. Adv Ther. 2023;40(3):869\u201386.","journal-title":"Adv Ther"},{"issue":"11","key":"1188_CR22","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/jdv.18376","volume":"36","author":"A Pinter","year":"2022","unstructured":"Pinter A, Puig L, Schakel K, et al. Comparative effectiveness of biologics in clinical practice: week\u00a012 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087\u2013100.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1188_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","volume":"45","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase\u00a0III study (SPIRIT-P1). J Rheumatol. 2018;45(3):367\u201377.","journal-title":"J Rheumatol"},{"issue":"1","key":"1188_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40744-020-00261-0","volume":"8","author":"AM Orbai","year":"2021","unstructured":"Orbai AM, Gratacos J, Turkiewicz A, et al. Efficacy and safety of ixekizumab in patients with psoriatic arthritis and inadequate response to TNF inhibitors: 3-year follow-up (SPIRIT-P2). Rheumatol Ther. 2021;8(1):199\u2013217.","journal-title":"Rheumatol Ther"},{"issue":"10086","key":"1188_CR25","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase\u00a03 trial. Lancet. 2017;389(10086):2317\u201327.","journal-title":"Lancet"},{"issue":"10","key":"1188_CR26","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","volume":"59","author":"V Chandran","year":"2020","unstructured":"Chandran V, van der Heijde D, Fleischmann RM, et al. Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase\u00a0III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020;59(10):2774\u201384.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1188_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1188_CR28","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week\u00a052. Ann Rheum Dis. 2020;79(10):1310\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1188_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40744-021-00388-8","volume":"9","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Okada M, Tillett W, et al. Ixekizumab demonstrates consistent efficacy versus adalimumab in biologic disease-modifying anti-rheumatic drug-naive psoriatic arthritis patients regardless of psoriasis severity: 52-week post hoc results from SPIRIT-H2H. Rheumatol Ther. 2022;9(1):109\u201325.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"1188_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase\u00a0III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1188_CR31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1188_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659\u201364.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"1188_CR33","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","volume":"78","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gottlieb A, Morita A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019;78(9):1215\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1188_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40273-013-0126-6","volume":"32","author":"A Torbica","year":"2014","unstructured":"Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics. 2014;32(2):209\u201323.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1188_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00403-015-1613-8","volume":"308","author":"C Blome","year":"2016","unstructured":"Blome C, Gosau R, Radtke MA, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69\u201378.","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"1188_CR36","first-page":"1221","volume":"49","author":"L Gossec","year":"2022","unstructured":"Gossec L, Walsh JA, Michaud K, et al. Effect of fatigue on health-related quality of life and work productivity in psoriatic arthritis: findings from a real-world survey. J Rheumatol. 2022;49(11):1221\u20138.","journal-title":"J Rheumatol"}],"updated-by":[{"DOI":"10.1007\/s13555-024-01221-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01188-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01188-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01188-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T06:31:17Z","timestamp":1720593077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01188-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01188-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13555-024-01221-0","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-024-01221-0","URL":"https:\/\/doi.org\/10.1007\/s13555-024-01221-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"April W. Armstrong has received grants or contracts from, and served as a consultant, speaker and\/or investigator for: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, UCB, Janssen, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Sun, Sanofi, and Regeneron; has participated on data safety monitoring or advisory boards for: Boehringer Ingelheim and Parexel; and has been elected to the Board of Directors for the American Academy of Dermatology. Tarannum Jaleel has served as a consultant and\/or investigator for: Eli Lilly and Company, Novartis, and UCB Pharma; and has received grants from: Dermatology Foundation, NIH K12, Pfizer-SOCS Grant, Skin of Colour Society, and UCB Pharma. Joseph F. Merola is a consultant and\/or investigator for: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Regeneron, Sun Pharma, and UCB Pharma. Alice B. Gottlieb receives research\/educational grants from: Highlights Therapeutics, Bristol Myers Squibb, Janssen and UCB Pharma\u2014all of which were paid to Mount Sinai School of Medicine; and has received honoraria as an advisory board member and consultant for: Amgen, AnaptypsBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Eli Lilly and Company, Highlights Therapeutics, Janssen, Novartis, Sanofi, Teva, UCB, and Xbiotech (stock options for RA). Saakshi Khattri has received grants or contracts from, and\/or served as a consultant and\/or speaker for: AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Incyte, Janssen, LEO Pharma, Pfizer, Regeneron, Sanofi, Arcutis, Bristol Myers Squibb, Incyte, Takeda, Boehringer Ingelheim, Novartis and UCB Pharma. Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, and Marcus E. Ngantcha are employees and shareholders of Eli Lilly and Company. Kurt de Vlam has received grant and\/or research support from: Celgene; and is a consultant for: Celgene, Eli Lilly and Company, Galapagos NV, Novartis, Pfizer, and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"SPIRIT-P1 and SPIRIT-P2 were conducted in accordance with Good Clinical Practice, the principles of the Declaration of Helsinki of 1964 and its later amendments, and local laws and regulations. SPIRIT-P1 was approved by the Western Institutional Review Board (approval #1-838258-1), and SPIRIT-P2 was approved by the Bellberry Human Research Ethics Committee (Application #2015-01-049-AA). For both studies, approval was also obtained from each additional site the full lists of investigators and sites are provided in the primary manuscript supplements [, ]. All patients in both studies gave written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}